Progress in the development of an adenovirus 26 vector platform for HIV vaccines.

about

Low seroprevalent species D adenovirus vectors as influenza vaccines.

P2860

Q30353263-BCB621BA-7A2D-4766-A2DB-EE66D2ACCEE5

P2860

Progress in the development of an adenovirus 26 vector platform for HIV vaccines.

Item

http://www.wikidata.org/entity/Q45865650

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Progress in the development of an adenovirus 26 vector platform for HIV vaccines.

@en

Progress in the development of an adenovirus 26 vector platform for HIV vaccines.

@nl

type

Item

label

Progress in the development of an adenovirus 26 vector platform for HIV vaccines.

@en

Progress in the development of an adenovirus 26 vector platform for HIV vaccines.

@nl

prefLabel

Progress in the development of an adenovirus 26 vector platform for HIV vaccines.

@en

Progress in the development of an adenovirus 26 vector platform for HIV vaccines.

@nl

P1476

Progress in the development of an adenovirus 26 vector platform for HIV vaccines.

@en

P2093

José Esparza

http://www.w3.org/2001/XMLSchema#string

P2860

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys.

Novel adenovirus vector-based vaccines for HIV-1.

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys

Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys.

P304

477-480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERV.13.26

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23659296

http://www.w3.org/2001/XMLSchema#string

P921

Adenoviridae

Progress in the development of an adenovirus 26 vector platform for HIV vaccines.

about

P2860

P2860

Progress in the development of an adenovirus 26 vector platform for HIV vaccines.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921